Vegenics Pty Limited
Records under this name other than the patents Vegenics Pty Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,274,503 | Methods of Using VEGF-C Biomarkers for Age-Related Macular Degeneration (AMD) Diagnosis Formerly held In force · High confidence | In force | High confidence | |
| US 11,209,444 | Treatment for age-related macular degeneration (AMD) and pathogenic ocular neovascularization Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,940,695 | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy Formerly held Term ended Term ended Nov 10, 2026 · Medium confidence | Term ended | Term ended Nov 10, 2026 | Medium confidence |
| US 7,846,437 | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same Term ended Term ended Mar 7, 2025 · USPTO record | Term ended | Term ended Mar 7, 2025 | USPTO record |
| US 7,534,572 | Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue Lapsed on the fee record Ended May 19, 2021 · USPTO record | Lapsed on the fee record | Ended May 19, 2021 | USPTO record |
| US 7,871,798 | Mammalian cells that express VEGF-D polypeptides Term ended Term ended Mar 24, 2019 · USPTO record | Term ended | Term ended Mar 24, 2019 | USPTO record |
| US 7,410,639 | Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use Term ended Term ended Mar 21, 2019 · USPTO record | Term ended | Term ended Mar 21, 2019 | USPTO record |
| US 7,122,654 | Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use Term ended Term ended Sep 14, 2018 · USPTO record | Term ended | Term ended Sep 14, 2018 | USPTO record |
| US 6,958,147 | Use of VEGF-C to prevent restenosis Lapsed on the fee record Ended Oct 25, 2017 · USPTO record | Lapsed on the fee record | Ended Oct 25, 2017 | USPTO record |
| US 7,785,803 | Antibody diagnostic kits and methods of use Term ended Term ended Oct 10, 2017 · USPTO record | Term ended | Term ended Oct 10, 2017 | USPTO record |